Opinions and recommendations of the Argentine Diabetes Society. Impaired fasting blood glucose: is it appropriate to use a cut-off point of 100 mg/dl in Argentina?
DOI:
https://doi.org/10.47196/diab.v57i1.676Keywords:
impaired fasting blood glucose, mellitus diabetes, prediabetes, recommendationsAbstract
To establish the cut-off point between normal and impaired fasting glycemia (IFG) is extremely important for the purposes of considering a patient at risk both of progressing to more advanced stages of the disease and of suffering micro- and macroangiopathic complications. Since 2006, the Argentine Diabetes Society (ADS), based on the evidence considered at that time, established the lower limit of IFG at 110 mg/dL, later, during the year 2022, The Board of Directors of the ADS convened a group of experts in order to assess whether this recommendation should be maintained or, like other prestigious scientific societies, adopt 100 gr/dL for this purpose.
This Opinions and Recommendations document contains the rationale for which the SAD will adopt, from now on, 100 mg/dL as the lower limit of the IFG, based on the new scientific evidence that shows that from this cut-off point it produces an increase in progression to diabetes and both macro and microangiopathic complications.
References
I. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997 Jul;20(7):1183-97. doi: 10.2337/diacare.20.7.1183. PMID: 9203460.
II. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979 Dec;28(12):1039-57. doi: 10.2337/diab.28.12.1039. PMID: 510803.
III. World Health Organization: Diabetes mellitus: report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727).
IV. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, World Health Org., 1999.
V. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P; Expert Committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003 Nov;26(11):3160-7. doi: 10.2337/diacare.26.11.3160. PMID: 14578255.
VI. Shaw JE, Zimmet PZ, Hodge AM, de Courten M, Dowse GK, Chitson P, Tuomilehto J, Alberti KG. Impaired fasting glucose: how low should it go? Diabetes Care 2000 Jan;23(1):34-9. doi: 10.2337/diacare.23.1.34. PMID: 10857965.
VII. Consenso Sociedad de Diabetología y Nutrición del Uruguay-Sociedad Argentina de Diabetes. Convergencias, divergencias, variabilidad, puntos de corte e indicación de la glucemia de ayuno, la hemoglobina glucosilada e insulinemia. Arch Med Interna 2010; XXXII (2-3): 41-49 © Prensa Médica Latinoamericana. 2010 ISSN 0250-3816. Disponible en file:///D:/Users/victor/Downloads/v32n2-3a05.pdf.
VIII. Faerch K, Borch-Johnsen K, Holst JJ, Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 2009 Sep;52(9):1714-23. doi: 10.1007/s00125-009-1443-3. Epub 2009 Jul 10. PMID: 19590846.
IX. American Diabetes Association Professional Practice Committee; American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022 Jan 1;45(Supplement_1):S17-S38. doi: 10.2337/dc22-S002. PMID: 34964875.
X. Atlas de la Diabetes de la FID. Novena edición 2019.
XI. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 Jul;15(7):539-53. doi: 10.1002/(SICI)1096-9136(199807)15:7<539:AID-DIA668>3.0.CO;2-S. PMID: 9686693.
XII. World Health Organization. Screening for type 2 diabetes. Report of a World Health Organization and International Diabetes Federation meeting. WHO/NMH/MNC/03.1 Geneva: WHO Department of Noncommunicable Disease Management. 2003
XIII. Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med 2008 Jun;121(6):519-24. doi: 10.1016/j.amjmed.2008.02.026. PMID: 18501234.
XIV. Munekawa C, Okada H, Hamaguchi M, Habu M, Kurogi K, Murata H, Ito M, Fukui M. Fasting plasma glucose level in the range of 90-99 mg/dl and the risk of the onset of type 2 diabetes: population-based Panasonic cohort study 2. J Diabetes Investig 2022 Mar;13(3):453-459. doi: 10.1111/jdi.13692. Epub 2021 Oct 23. PMID: 34624178; PMCID: PMC8902401.
XV. Kato M, Noda M, Suga H, Matsumoto M, Kanazawa Y. Fasting plasma glucose and incidence of diabetes implication for the threshold for impaired fasting glucose: results from the population-based Omiya MA cohort study. J Atheroscler Thromb 2009;16(6):857-61. doi: 10.5551/jat.1792. Epub 2009 Dec 22. Erratum in: J Atheroscler Thromb. 2010 Mar 31;17(3):315. PMID: 20032586.
XVI. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003 Jan;46(1):3-19. doi: 10.1007/s00125-002-1009-0. Epub 2003 Jan 11. PMID: 12637977.
XVII. Fernández-Castañer M, Biarnés J, Camps I, Ripollés J, Gómez N, Soler J. Beta-cell dysfunction in first-degree relatives of patients with non-insulin-dependent diabetes mellitus. Diabet Med 1996 Nov;13(11):953-9. doi: 10.1002/(SICI)1096-9136(199611)13:11<953::AID-DIA257>3.0.CO;2-V. PMID: 8946153.
XVIII. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005 Jan;90(1):493-500. doi: 10.1210/jc.2004-1133. Epub 2004 Oct 13. PMID: 15483086.
XIX. Mengozzi A, Tricò D, Nesti L, Petrie J, Højlund K, Mitrakou A, Krebs M, Mari A, Natali A; RISC Investigators. Disruption of fasting and post-load glucose homeostasis are largely independent and sustained by distinct and early major beta-cell function defects: a cross-sectional and longitudinal analysis of the Relationship between Insulin Sensitivity and Cardiovascular risk (RISC) study cohort. Metabolism 2020 Apr;105:154185. doi: 10.1016/j.metabol.2020.154185. Epub 2020 Feb 14. PMID: 32061908.
XX. Kanat M, Mari A, Norton L, Winnier D, DeFronzo RA, Jenkinson C, Abdul-Ghani MA. Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes 2012 Feb;61(2):447-53. doi: 10.2337/db11-0995. PMID: 22275086; PMCID: PMC3266412.
XXI. Prentki M, Peyot ML, Masiello P, Madiraju SRM. Nutrient-induced metabolic stress, adaptation, detoxification, and toxicity in the pancreatic β-cell. Diabetes 2020 Mar;69(3):279-290. doi: 10.2337/dbi19-0014. PMID: 32079704.
XXII. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, Klein R, Klein BE, Zimmet P, Shaw J. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 2008 Mar 1;371(9614):736-43. doi: 10.1016/S0140-6736(08)60343-8. Erratum in: Lancet. 2008 May 31;371(9627):1838. PMID: 18313502; PMCID: PMC2350208.
XXIII. Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology 1998 Mar;105(3):406-11. doi: 10.1016/S0161-6420(98)93019-6. PMID: 9499768.
XXIV. Dunstan DW, Zimmet PZ, Welborn TA, Cameron AJ, Shaw J, de Courten M, Jolley D, McCarty DJ; Australian Diabetes, Obesity and Lifestyle Study (AusDiab). The Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Methods and response rates. Diabetes Res Clin Pract 2002 Aug;57(2):119-29. doi: 10.1016/s0168-8227(02)00025-6. PMID: 12062857.
XXV. Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, Sharrett AR, Shea S. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006 Mar;141(3):446-455. doi: 10.1016/j.ajo.2005.08.063. PMID: 16490489; PMCID: PMC2246042.
XXVI. Chaila MZ, et al. Glucemia en ayunas entre 100 y 109 mg/dl versus prediabetes según hemoglobina glicosilada. Rev Soc Arg Diab 2022;56(2):52-57.
XXVII. Cheng YJ, Gregg EW, Geiss LS, Imperatore G, Williams DE, Zhang X, Albright AL, Cowie CC, Klein R, Saaddine JB. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care 2009 Nov;32(11):2027-32. doi: 10.2337/dc09-0440. PMID: 19875604; PMCID: PMC2768189.
XXVIII. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003 Mar;26(3):688-96. doi: 10.2337/diacare.26.3.688. PMID: 12610023.
XXIX. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016 Nov 23;355:i5953. doi: 10.1136/bmj.i5953. PMID: 27881363; PMCID: PMC5121106.
XXX. Bergman M, Abdul-Ghani M, DeFronzo RA, Manco M, Sesti G, Fiorentino TV, Ceriello A, Rhee M, Phillips LS, Chung S, Cravalho C, Jagannathan R, Monnier L, Colette C, Owens D, Bianchi C, Del Prato S, Monteiro MP, Neves JS, Medina JL, Macedo MP, Ribeiro RT, Filipe-Raposo J, Dorcely B, Ibrahim N, Buysschaert M. Review of methods for detecting glycemic disorders. Diabetes Res Clin Pract 2020 Jul;165:108233. doi: 10.1016/j.diabres.2020.108233. Epub 2020 Jun 1. Erratum in: Diabetes Res Clin Pract. 2021 Oct;180:108632. PMID: 32497744; PMCID: PMC7977482.
XXXI. Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G. Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016. JAMA Pediatr 2020 Feb 1;174(2):e194498. doi: 10.1001/jamapediatrics.2019.4498. Epub 2020 Feb 3. PMID: 31790544; PMCID: PMC6902249.
XXXII. TODAY Study Group, Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, Tesfaldet B, Tryggestad J, White NH, Zeitler P. Long-term complications in youth-onset type 2 diabetes. N Engl J Med 2021 Jul 29;385(5):416-426. doi: 10.1056/NEJMoa2100165. PMID: 34320286; PMCID: PMC8697255.
XXXIII. Utzschneider KM, Tripputi MT, Kozedub A, Barengolts E, Caprio S, Cree-Green M, Edelstein SL, El Ghormli L, Hannon TS, Mather KJ, Palmer J, Nadeau KJ; RISE Consortium. Differential loss of β-cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study. Diabetes Res Clin Pract 2021 Aug;178:108948. doi: 10.1016/j.diabres.2021.108948. Epub 2021 Jul 15. PMID: 34274407; PMCID: PMC8628318.
XXXIV. Casagrande SS, Menke A, Linder B, Osganian SK, Cowie CC. Cardiovascular risk factors in adolescents with prediabetes. Diabet Med 2018 May 5:10.1111/dme.13661. doi: 10.1111/dme.13661. Epub ahead of print. PMID: 29729052; PMCID: PMC6218322.
XXXV. Wallace AS, Wang D, Shin JI, Selvin E. Screening and diagnosis of prediabetes and diabetes in US children and adolescents. Pediatrics 2020 Sep;146(3):e20200265. doi: 10.1542/peds.2020-0265. Epub 2020 Aug 10. PMID: 32778539; PMCID: PMC7461138.
XXXVI. Dwyer T, Sun C, Magnussen CG, Raitakari OT, Schork NJ, Venn A, Burns TL, Juonala M, Steinberger J, Sinaiko AR, Prineas RJ, Davis PH, Woo JG, Morrison JA, Daniels SR, Chen W, Srinivasan SR, Viikari JS, Berenson GS. Cohort Profile: the International Childhood Cardiovascular Cohort (i3C) Consortium. Int J Epidemiol 2013 Feb;42(1):86-96. doi: 10.1093/ije/dys004. Epub 2012 Mar 20. PMID: 22434861; PMCID: PMC3600617.
XXXVII. Cleland V, Tian J, Buscot MJ, Magnussen CG, Bazzano L, Burns TL, Daniels S, Dwyer T, Hutri-Kahonen N, Ikonen J, Jacobs D, Juonala M, Prineas R, Raitakari O, Sinaiko A, Steinberger J, Urbina EM, Woo JG, Venn A. Body-mass index trajectories from childhood to mid-adulthood and their sociodemographic predictors. Evidence from the International Childhood Cardiovascular Cohort (i3C) Consortium. E Clinical Medicine 2022 May 12;48:101440. doi: 10.1016/j.eclinm.2022.101440. PMID: 35706485; PMCID: PMC9112099.
XXXVIII. Brambilla P, La Valle E, Falbo R, Limonta G, Signorini S, Cappellini F, Mocarelli P. Normal fasting plasma glucose and risk of type 2 diabetes. Diabetes Care 2011 Jun;34(6):1372-4. doi: 10.2337/dc10-2263. Epub 2011 Apr 15. PMID: 21498787; PMCID: PMC3114342.
XXXIX. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002 Dec;25(12):2165-71. Doi: 10.2337/diacare.25.12.2165. PMID: 12453955; PMCID: PMC1282458.
XL. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006 Sep;29(9):2102-7. doi: 10.2337/dc06-0560. PMID: 16936160; PMCID: PMC1762038.
XLI. Echouffo-Tcheugui JB, Selvin E. Prediabetes and what it means: the epidemiological evidence. Annu Rev Public Health 2021 Apr 1;42:59-77. doi: 10.1146/annurev-publhealth-090419-102644. Epub 2021 Dec 23. PMID: 33355476; PMCID: PMC8026645.
XLII. Sereday M, Arias P, Bragagnolo JC, Burlando G, Cédola N, Commendatore V, Costa Gil JE, Damiano M, Dieuzeide G, Domínguez JM, Eandi ML, Faingold MC, Ferraro M, Frechtel G, Gagliardino JJ, González C, Lapertosa S, Libman J, Luaces MC, Martí ML, Maselli M del C, Mazza CS, Moser M, Ozuna B, Puchulu, FM, Rebolledo O, Rodríguez Papini N, Viñes G. Consenso sobre criterio diagnóstico de la glucemia alterada de ayunas. Sociedad Argentina de Diabetes, 6 de mayo de 2006. Rev Soc Arg Diab 2007;41(3):96-104
XLIII. Programa de Evaluación Externa de Calidad (PEEC) de la Fundación Bioquímica Argentina (FBA).
XLIV. Programa Internacional Buenos Aires de Control de Calidad Externo en Análisis Clínicos. ProgBA.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
